Victory Capital Management
ELDN icon

Victory Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Victory Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-138
Closed -$1K – 2739
2020
Q1 		$1K Buy
+138
New +$1.32K ﹤0.01% 3607
2019
Q4 		– Sell
-117
Closed -$1K – 2830
2019
Q3 		$1K Buy
+117
New +$1.68K ﹤0.01% 3696

Other funds holding ELDN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Victory Capital Management's ELDN Position: Q2 2020 in Review

Victory Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q2 2020, closing a stake of 138 shares — an estimated $1K sold.

Victory Capital Management first reported a position in ELDN in Q3 2019 and held it in 2 quarters. The position peaked at $1K in Q1 2020. 20 funds tracked by Wall St. Rank hold ELDN as of Q2 2020.

  • Victory Capital Management reported no remaining Eledon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 138 Eledon Pharmaceuticals shares in Q2 2020, an estimated $1K.
  • Victory Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Eledon Pharmaceuticals position peaked at $1K in Q1 2020.
  • 20 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.